URGENT: This Altcoin Opportunity Won’t Wait – Act Now

Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.

Barry Ticho Biography and Net Worth

Insider of Stoke Therapeutics

Barry Ticho is the chief medical officer at Stoke Therapeutics, where he is helping to lead the company’s efforts to develop first-in-class therapeutics to treat rare diseases. Prior to joining Stoke, Barry was most recently head of development of mRNA treatments for cardiovascular and metabolic diseases at Moderna Therapeutics. Before Moderna, he was head of external R&D innovation for cardiovascular and metabolic diseases at Pfizer, and before that, he was vice president of clinical development at Biogen. Barry obtained his M.D. and Ph.D. degrees from the University of Chicago. He completed pediatrics training at Northwestern University and a cardiology fellowship at Boston Children’s Hospital. Barry has also served as a member of the clinical staff at Harvard Medical School and Massachusetts General Hospital, where he conducted laboratory research on the regulation of cardiac development.

What is Barry Ticho's net worth?: The estimated net worth of Barry Ticho is at least $522,633.28 as of December 9th, 2024. Dr. Ticho owns 44,746 shares of Stoke Therapeutics stock worth more than $522,633 as of December 21st. This net worth estimate does not reflect any other investments that Dr. Ticho may own. Additionally, Dr. Ticho receives an annual salary of $684,550.00 as Insider at Stoke Therapeutics. Learn More about Barry Ticho's net worth.
How old is Barry Ticho?: Dr. Ticho is currently 63 years old. There are 7 older executives and no younger executives at Stoke Therapeutics. The oldest executive at Stoke Therapeutics is Dr. Edward M. Kaye M.D., Ph.D., CEO & Director, who is 75 years old. Learn More on Barry Ticho's age.
What is Barry Ticho's salary?: As the Insider of Stoke Therapeutics, Inc., Dr. Ticho earns $684,550.00 per year. The highest earning executive at Stoke Therapeutics is Dr. Edward M. Kaye M.D., Ph.D., CEO & Director, who commands a salary of $948,900.00 per year. Learn More on Barry Ticho's salary.
How do I contact Barry Ticho?: The corporate mailing address for Dr. Ticho and other Stoke Therapeutics executives is 45 WIGGINS AVENUE, BEDFORD MA, 01730. Stoke Therapeutics can also be reached via phone at (781) 430-8200 and via email at [email protected]. Learn More on Barry Ticho's contact information.
Has Barry Ticho been buying or selling shares of Stoke Therapeutics?: During the last ninety days, Barry Ticho has sold $332,509.24 in Stoke Therapeutics stock. Most recently, Barry Ticho sold 2,586 shares of the business's stock in a transaction on Monday, December 9th. The shares were sold at an average price of $12.99, for a transaction totalling $33,592.14. Following the completion of the sale, the insider now directly owns 44,746 shares of the company's stock, valued at $581,250.54. Learn More on Barry Ticho's trading history.
Who are Stoke Therapeutics' active insiders?: Stoke Therapeutics' insider roster includes Edward Kaye (), Huw Nash (COO), and Barry Ticho (Insider). Learn More on Stoke Therapeutics' active insiders.
Are insiders buying or selling shares of Stoke Therapeutics?: In the last twelve months, insiders at the sold shares 16 times. They sold a total of 5,653,090 shares worth more than $70,209,310.82. The most recent insider tranaction occured on December, 9th when insider Barry Ticho sold 2,586 shares worth more than $33,592.14. Insiders at Stoke Therapeutics own 11.3% of the company. Learn More about insider trades at Stoke Therapeutics.
Information on this page was last updated on 12/9/2024.

Barry Ticho Insider Trading History at Stoke Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/9/2024	Sell	2,586	$12.99	$33,592.14	44,746
12/6/2024	Sell	13,945	$12.78	$178,217.10	47,332
12/2/2024	Sell	10,000	$12.07	$120,700.00	51,277
7/1/2024	Sell	10,000	$13.75	$137,500.00	2,485
2/1/2024	Sell	10,000	$4.80	$48,000.00	6,981
1/2/2024	Sell	10,000	$5.74	$57,400.00	16,981
7/3/2023	Sell	15,000	$10.60	$159,000.00	25,895
6/1/2023	Sell	15,000	$11.13	$166,950.00	40,895
5/3/2023	Sell	24,697	$10.14	$250,427.58	56,548
5/1/2023	Sell	24,967	$10.00	$249,670.00	86,758
2/6/2023	Sell	9,235	$10.02	$92,534.70	111,725
2/2/2023	Sell	267	$10.00	$2,670.00	124,723
1/31/2023	Sell	200	$10.00	$2,000.00	130,695
7/13/2021	Sell	43,166	$32.75	$1,413,686.50
12/21/2020	Sell	1,365	$57.62	$78,651.30
6/1/2020	Sell	1,365	$27.39	$37,387.35	131,147

Barry Ticho Buying and Selling Activity at Stoke Therapeutics

Stoke Therapeutics Company Overview

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

Today's Range

Now: $11.68

$10.81

$11.84

50 Day Range

MA: $12.48

$11.11

$13.92

2 Week Range

Now: $11.68

$4.09

$17.58

Volume

1,156,170 shs

Average Volume

744,608 shs

Market Capitalization

$618.65 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.95

Did You See Trump’s Bombshell Exec. Order 001?

From Banyan Hill Publishing | Ad

Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."

I put all the details together for you here — but please hurry.

Barry Ticho Biography and Net Worth

What is Barry Ticho's net worth?

How old is Barry Ticho?

What is Barry Ticho's salary?

How do I contact Barry Ticho?

Has Barry Ticho been buying or selling shares of Stoke Therapeutics?

Who are Stoke Therapeutics' active insiders?

Are insiders buying or selling shares of Stoke Therapeutics?